Houston Man Beats Stage II Lung Cancer After Second Opinion

When Daniel West's routine heart scan revealed two nodules on his lungs in October 2022, the fit, active 52-year-old couldn't believe it. He'd quit smoking 16 years earlier and lived a healthy life, yet here he was facing the same lung cancer that took his grandfather's life.

The Houston native's journey took a crucial turn when he sought a second opinion at UT MD Anderson Cancer Center. His original surgeon planned to remove just one cancerous nodule, but Daniel had another nodule that wasn't addressed in the treatment plan.

"We didn't feel completely comfortable with the treatment," Daniel recalls. So he and his husband John requested an appointment at MD Anderson online and got a response the same day.

What happened next changed everything. On his first appointment in January 2023, Daniel met with a thoracic oncologist, a thoracic surgeon, and his entire care team together. At his previous hospital, he'd only spoken with a surgeon.

Dr. Wayne Hofstetter performed a robotic lobectomy in February 2023, removing Daniel's middle right lung lobe and 14 lymph nodes for testing. Three tested positive for cancer, updating his diagnosis from early-stage to stage IIB.

Daniel completed four cycles of chemotherapy through June 2023, rang the hospital's celebratory bell, and began targeted therapy with osimertinib. Testing revealed his tumor was EGFR positive, a mutation often found in nonsmokers that responds well to targeted treatment.

For more than two years now, Daniel's scans have shown no evidence of active disease. Doctors continue monitoring other nodules in his lung, none of which have grown.

Why This Inspires

Daniel's story highlights a truth many cancer patients discover too late: comprehensive care teams make a difference. Having multiple specialists work together from day one meant nothing was overlooked in his treatment plan.

His EGFR-positive diagnosis also represents real progress in cancer care. Just years ago, nonsmoker lung cancer was poorly understood. Today, genetic testing identifies specific mutations that respond to targeted pills rather than harsh traditional treatments alone.

Most importantly, Daniel's willingness to seek a second opinion likely saved his life. Getting multiple perspectives on serious diagnoses isn't questioning your doctor, it's being your own best advocate.

Daniel will continue his daily targeted therapy pill through June 2026, a small price for the active, healthy life he's reclaimed with John by his side.

##